MA-NUMARES
Leading NMR diagnostics company numares AG appoints Dr. Gregory Heath as new member of the Supervisory Board. Dr. Heath has a long career in the diagnostics and life sciences industry, including long-term experience in the development and launching of in vitro diagnostics (IVDs). He will assist numares in the commercialization of multi-marker-based diagnostic tests running on the company’s proprietary, AI-driven IVD platform, the AXINON® System , for which the company applied for two 510(k) clearances this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005040/en/
“We are delighted to welcome Greg to the board,” said Dr. Volker Pfahlert, Chief Executive Officer of numares . “As we continue our focus on expansion in the United States, his depth of knowledge and substantial experience in the US diagnostics industry will help drive our diagnostic strategy and be invaluable to numares as it launches IVD products."
With his appointment, Dr. Heath joins the numares Supervisory Board as the second, independent US expert after Ms. Kathy Bates of Mayo Clinic Laboratories, who has been supporting the Supervisory Board as first US advisor since her election in 2019.
He brings with him more than 30 years of diagnostics experience. As a former General Manager of Diagnostics at Illumina Inc., Dr. Heath was responsible for building and managing the molecular Diagnostics Business Unit, as well as for the establishment of a CLIA lab and acquisition of service labs. Prior to this, he was SVP, Molecular Business at Roche Diagnostics, and held numerous roles in strategy, marketing, and business development during his career. He currently serves on the Scientific Advisory Board of Everlywell and is a strategic and scientific advisor to the diagnostics and life sciences industry.
Winton Gibbons, President of numares GROUP in the US and co-CEO of numares AG adds "Greg is a great addition to our Supervisory Board. His extensive experience in the diagnostics industry will help numares to commercialize its pipeline of new tests in the US. These include AXINON® GFR(NMR) , a novel multi-marker kidney function test, recently submitted for FDA clearance."
Earlier this year, numares also announced its FDA 510(k) application for the AXINON® LDL-P test on the AXINON® System , an IVD platform based on Nuclear Magnetic Spectroscopy (NMR), combined with the company’s proprietary Magnetic Group Signaling (MGS® ). MGS® enables simultaneous, highly standardized analysis of metabolites in human samples like blood and urine. The platform is used to develop and deploy novel diagnostic tests in clinical laboratories, applying the “numares model, ” that identifies a set of metabolites, so-called "biomarker constellations,” via machine learning algorithms. This provides diagnostics solutions for the prevention and treatment of disease, including conditions in the kidney, heart, and liver, as well as cancer.
At the numares shareholders’ meeting in December 2021, Dr. Heath was elected as member of the supervisory board effective January 1st, 2022.
You will find more information at https://www.numares.com/ and on our social media channels: LinkedIn , Facebook , YouTube and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005040/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duco introduces agentic workspace; a new collaboration layer for intelligent operations19.11.2025 10:00:00 CET | Press release
Duco, the trusted control layer in an agentic world, today announced the launch of agentic workspace, a new capability within the Duco Platform designed to help operations teams work alongside intelligent agents with transparency, control and confidence. Agentic workspace is a collaboration environment where users can build, maintain, optimise, manage tasks and exceptions. All within a single, auditable workspace. It brings humans and autonomous agents together in a shared operational context, ensuring interoperability between systems while maintaining full oversight and explainability. “Agentic workspace is the next step in our mission to put people in control of automated operations,” said James Maxfield, Chief Product Officer at Duco. “As firms embrace agentic AI, they need tools that allow them to monitor, adjust and collaborate with these systems in real time. This workspace gives them that control, without slowing innovation.” By combining data automation, exception management an
Quectel Takes Smart Meters to the Next Generation at Enlit 202519.11.2025 10:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, has announced it is attending the Enlit 2025 event in Bilbao, Spain on 18-20 November 2025 and will be at Stand 1.G86. Quectel is attending to showcase how its comprehensive range of modules, antennas and services are poised to assist continued massive uptake of smart meters and assist industry moves from first to second-generation devices. With deployments of smart meters, comprised of electricity, water and gas meters, exceeding 1.06 billion at the end of 2023 and set to continue in all regions, according to IoT Analytics, Quectel is seeing growth across all meter types and expansion of meter-based use cases. Smart electricity meters are being deployed in developing markets for the first time and mature markets are accelerating deployments of second-generation smart meters to help users optimize consumption and manage their own power generation via two-way metering communications. Growth is being experienced acr
Pacsun Successfully Implements Manhattan Active® Point of Sale, Unifying Commerce and Cutting Checkout Times19.11.2025 09:00:00 CET | Press release
Manhattan Associates Inc. (NASDAQ: MANH) today announced that Pacsun, a leading youth fashion retailer, has successfully deployed Manhattan Active® Point of Sale (POS), a cloud-native in-store sales and service solution that empowers associates to merge digital convenience with personalised retailing. Following a five-month project start to pilot phase, Pacsun rolled out Manhattan's POS solution across 300 plus stores in just eight weeks. Mobile checkout capabilities eased long in-store lines, while unified inventory management, powered by RFID integration, supported seamless fulfilment across Instagram, Amazon, TikTok and Pacsun’s own channels. During peak holiday season, Pacsun achieved record breaking revenue and streamlined operations, with 40% of online orders being fulfilled via stores, optimising inventory proximity, labour capacity and shipping costs that reduced logistics expenses by 25%. Stores are now critical drivers of retail differentiation, with industry research showing
Frontgrade Gaisler and DELTATEC Enable Advanced Space Computing Across Multiple Missions19.11.2025 09:00:00 CET | Press release
Frontgrade™ Gaisler Technologies a leading provider of high-reliability electronic solutions for space and national security missions, and DELTATEC,a very high-level design house specialized in advanced technologies are pleased to celebrate their successful collaboration in delivering high-performance computing solutions for space applications, with the GR712RC dual-core microprocessor at the heart of several flight-proven systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119011567/en/ The GR712RC, developed by Frontgrade Gaisler and based on the fault-tolerant LEON3FT architecture, has been integrated into multiple Data Handling System (DHS) units designed by DELTATEC. These include one Payload Data Handling Unit (PDHU) and two On-Board Computers (OBCs) currently operating aboard ESA’s eSAIL mission, launched into Low Earth Orbit (LEO) in September 2020. Moreover, DELTATEC recently delivered the Flight Model of the
AGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human Mortality19.11.2025 09:00:00 CET | Press release
Partnership leverages AGC Biologics’ cost-effective and dependable cGMP mRNA and LNP capabilities AGC Biologics today announced it is partnering with Repair Biotechnologies to tackle one of the world's most persistent health challenges and cause of mortality. The collaboration will focus on developing and manufacturing a novel mRNA therapy to rapidly stabilize and reduce the size of atherosclerotic plaques in major blood vessels. Rupture of unstable plaque and subsequent heart attack or stroke is the leading cause of death, accounting for 27% of all human mortality. “Developing a novel mRNA therapeutic as a part of the vital goal of curing atherosclerotic cardiovascular disease is a complex task, and robust manufacturing is critical to our progress,” said Reason, CEO and co-founder, Repair Biotechnologies. “We chose AGC Biologics because they have mastered the entire production chain for therapeutics of this class, eliminating critical risks and delays to provide a fast and reliable pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom